论文部分内容阅读
目的探讨厄贝沙坦对中老年男性原发性高血压(primary hypertension,PH)患者骨质代谢的影响。方法回顾性分析,随机选择年龄在40~89岁的中老年男性PH患者94例。按服用治疗高血压药物的类别分为2组:厄贝沙坦治疗组(34例,长期服用治疗剂量厄贝沙坦)和对照组[60例,服用非血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)类药物]。分别比较2组血清钙、磷浓度、碱性磷酸酶(alkaline phosphatase,ALP)浓度、骨密度(bone mineral density,BMD)、骨折发生率的差异。结果厄贝沙坦治疗组患者股骨颈部、股骨总和、腰椎部位BMD和BMD与正常成人峰值比较积分(T值)相较于非ACEI/ARB类药物治疗组显著增加。结论厄贝沙坦对于中老年男性PH患者具有一定的骨保护作用。
Objective To investigate the effect of irbesartan on the bone metabolism in middle-aged and elderly patients with primary hypertension (PH). Methods Retrospective analysis of 94 elderly PH patients aged 40 to 89 years old were randomly selected. According to the types of drugs used for treatment of hypertension, the patients were divided into two groups: irbesartan group (34 patients, long-term treatment dose irbesartan) and control group (60 patients, taking non-angiotensin converting enzyme inhibitor ) / Angiotensin Ⅱ receptor blocker (ARB) drugs]. The levels of serum calcium and phosphorus, alkaline phosphatase (ALP), bone mineral density (BMD) and fracture incidence were compared between the two groups. Results Compared with non-ACEI / ARB group, the scores of femoral neck, femur, lumbar BMD and BMD in the irbesartan group were significantly higher than those in the normal adults (T value). Conclusion Irbesartan has certain bone protective effect on PH in middle-aged and elderly men.